참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Cetirizine | HCID 2678 | — |
| 반응물 | 4-((4-Chlorophenyl)phenylmethyl)-1-piperazineethanol | HCID 3419898 | — |
| 반응물 | Potassium | HCID 5462222 | — |
| 반응물 | Potassium tert-butoxide | HCID 23665647 | — |
| 반응물 | Sodium chloroacetate | HCID 23665759 | — |
| 생성물 | Cetirizine Hydrochloride | HCID 55182 | 48.8% |
반응 단계
The process of UK-P No. 2 225 320 (Chem. Abstr., 113, 191395s) aims at the elimination of the disadvantages of the above known processes by preparing cetirizine from the {2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol of the formula III which is converted to the potassium salt with potassium tert-butylate. The potassium salt is reacted with sodium chloro-acetate to obtain cetirizine dihydrochloride in a yield of 48.8%. In addition, 5.1% of a second generation product are obtained. Also an improved process is described for the preparation of the {2-[4-(α-phenyl-p-chlorobenzyl)piperazin-1-yl]}ethanol of the formula III according to which 1-[(4-chlorophenyl)phenyl-methyl]piperazine of the formula VI is reacted with ethylene chlorohydrine in a yield of 90.4%, the total yield of the synthesis, referred to the piperazine derivative of the formula VI, is merely 48.7%.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US06908999B2 |
|---|
| 출처 데이터셋 | uspto-grants-2005_06 |
|---|
| ORD ID | ord-a63f0f0fe1ef487fa2253d6c3dd5f958 |
|---|
| 출처 메모 | uspto-grants-2005_06 |
|---|